Navigation Links
Micromet, Inc. Reports Third Quarter 2008 Financial Results
Date:11/6/2008

the drug to be well tolerated and suggest that adding adecatumumab to standard chemotherapy could be a valuable treatment option for patients with high EpCAM expression.

-- On September 30, Micromet announced that it had entered into a definitive agreement to raise $40 million in a private placement of its common stock and warrants. The net proceeds of the private placement in the amount of $37.4 million were received on October 2, 2008. This financing increased the Company's cash and cash equivalents to approximately $53 million at the beginning of the fourth quarter of 2008.

"The accomplishments of the third quarter illustrate our commitment to a strategy of disciplined execution, focused on fundamentals, with the goal of building Micromet into a leading biotechnology company," commented Christian Itin, Ph.D., President and Chief Executive Officer of Micromet.

Financial Results:

Quarter Ended September 30, 2008

For the three months ended September 30, 2008, Micromet recognized total revenues of $7.0 million, compared to $5.6 million for the same period in 2007. Total operating expenses were $13.4 million for the three months ended September 30, 2008, compared to $9.2 million for the same period in 2007.

Loss from operations for the three months ended September 30, 2008 was $6.3 million, compared to a loss from operations of $3.6 million for the same period in 2007.

For the three months ended September 30, 2008, Micromet reported a net loss of $12.9 million, or $0.31 per basic and diluted common share, compared to a net loss of $2.3 million, or $0.06 per basic and diluted common share, for the same period in 2007. The net loss for the three months ending September 30, 2008 includes a non-cash charge of $6.8 million reflecting a change in the fair value of warrants issued in connection with a 2007 PIPE financing. The Company recorded a $1.2 million non-cash gain for this item in the third quarter of 2007.

Nine
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results
2. Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
3. Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
4. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
5. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
7. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
8. EntreMed Reports Third Quarter 2008 Financial Results
9. CV Therapeutics Reports 2008 Third Quarter Financial Results
10. Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2008 Results and Announces Share Repurchase
11. Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... July 23, 2014 ... of Trendlines Agtech , announced it has ... Israel,s leading agricultural thermoplastics applications companies. ... Valentis,s technology combines nanocrystalline cellulose (NCC), a biodegradable, ... additional nanoparticles to produce highly improved polymeric films. ...
(Date:7/23/2014)... MOINES, Iowa (PRWEB) July 23, 2014 ... join the business as vice president of Agricultural Biotechnology ... Mendel Biotechnology where he served most recently as president, ... extensive biotechnology and business leadership in the seed and ... Pioneer,” said Paul E. Schickler , president of ...
(Date:7/23/2014)... , July 23, 2014 /PRNewswire/ - BioAmber ... biotechnology company producing sustainable chemicals, today announced that the ... full their option to purchase an additional 420,000 ... price of $12.00 per share, less underwriting discounts ... underwritten public offering of 2,800,000 shares of common ...
(Date:7/23/2014)... regulated information -- UCB today announced an ... with positive topline results from the latest Phase ... designed to evaluate the efficacy and safety of ... titration) compared to placebo, as adjunctive treatment in ... fully controlled despite treatment with one or two ...
Breaking Biology Technology:Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7
... April 9, 2012 The University of Southern California Marshall ... announced its 6th Annual Marshall School of Business Leadership ... 11:00 am to 5:30 pm, at Los Angeles, newest landmark, ... (Logo: http://photos.prnewswire.com/prnh/20120409/LA84249LOGO ) A new dynamic ...
... WALTHAM, Mass., April 9, 2012   Syndax Pharmaceuticals, ... that investigators at The University of Texas MD ... have initiated a phase 1/2 study combining Syndax,s ... patients with locally recurrent or distant relapsed metastatic ...
... Carbon Limited today announces that they will be exhibiting at ... sheet of carbon just one atom thick, has been described ... University in 2004, for which the team was awarded a ... commercially. To support this work the UK Government recently ...
Cached Biology Technology:USC Marshall School of Business 6th Annual Leadership Summit 2USC Marshall School of Business 6th Annual Leadership Summit 3Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer 2Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer 3UK company to demonstrate their commercially effective graphene production process 2
(Date:7/23/2014)... blood-brain barrier damage appear after cerebral infarction, ... metalloproteinase-9 is able to degrade the major ... blood vessels and to mediate extracellular matrix ... from the First Affiliated Hospital of Medical ... cerebral infarction in stroke-prone spontaneously hypertensive rats ...
(Date:7/23/2014)... Neuroprotection by ischemic preconditioning has been confirmed by ... In a study released in the Neural ... Dr. Yong Liu and co-workers from Tongji Hospital ... Science and Technology, China performed cerebral ischemic preconditioning ... and explored the mechanism underlying the neuroprotective effect ...
(Date:7/23/2014)... region of the brain is important for ... the underlying mechanisms are unclear. Dr. Zhouyan ... monitored the activity of hippocampal neurons in ... mechanisms underlying the neuronal responses. Somatosensory stimulation, ... local field potentials into theta rhythm-dominated waveforms, ...
Breaking Biology News(10 mins):
... Department of Health Policy and Management at Columbia,s ... of pollution on agricultural worker productivity using daily ... ozone, even at levels below current air-quality standards ... negative impacts on worker productivity. Their findings suggest ...
... Department of Energy,s National Renewable Energy Laboratory (NREL) will ... in a five-year, $7 million effort to economically produce ... feedstocks, the federal laboratory announced today. The work ... Agreement (CRADA) between NREL and Johnson Matthey. "It,s ...
... Scientists at The University of Manchester have used synchrotron-based imaging ... Their work on a 50 million year old lizard ... demonstrating for the first time that this fossil animal was ... using some of the brightest light in the universe, x-rays ...
Cached Biology News:Ozone levels have sizeable impact on worker productivity 2NREL and Johnson Matthey announce 5-year collaboration on biofuels 2Prehistoric ghosts revealing new details 2
... P20 plus,for Reliable Sterile Filtration of Tissue ... a,membrane pump or tube pump, quickly and,reliably ... media,and aqueous solutions. The combination of ... automatic de-aeration,ensures high flow rates and optimal ...
... fluorescent microscopy-based imaging system that accurately counts ... calculates cell viability, in a single test. ... variability associated with the subjective interpretation of ... EasyCount ViaSure Kit, up to six tests ...
... The new Adept CE 4100 high ... superb flow precision, with software drive compensation, ... from 0.001-10mL/min are selectable in 0.001mL steps. ... are inert and bio-compatible., Pumps may be ...
... membrane and filter paper sandwiches are composed ... two sheets of thick filter paper that ... filter paper sandwich. These 7 x 8.5 ... immunoblotting fit Ready Gel-sized gels and are ...
Biology Products: